Austin, Texas & New York, August 5, 2026
The Foundation for Angelman Syndrome Therapeutics (FAST) has announced a strategic agreement with Apertura Gene Therapy to accelerate the development of next-generation gene therapies for Angelman syndrome by gaining access to TfR1 CapX™, Apertura’s proprietary blood-brain barrier (BBB)-crossing adeno-associated virus (AAV) capsid technology. The collaboration is designed to support investigational gene therapy programs focused on restoring UBE3A gene function, the underlying genetic cause of Angelman syndrome. By leveraging an advanced capsid capable of crossing the blood-brain barrier after intravenous administration, FAST aims to overcome one of the most significant scientific obstacles in central nervous system (CNS) gene therapy. The partnership reflects the growing importance of combining innovative delivery technologies with disease-focused research to accelerate the development of transformative treatments for patients living with rare neurogenetic disorders.
Innovative AAV Capsid Technology Targets CNS Drug Delivery
A central focus of the collaboration is TfR1 CapX™, Apertura Gene Therapy’s next-generation AAV capsid platform engineered to bind human transferrin receptor 1 (hTfR1), enabling therapeutic genes to cross the blood-brain barrier following intravenous administration. Efficient delivery of gene therapies into the central nervous system has remained one of the greatest technical challenges in treating neurological disorders, as conventional viral vectors often have limited brain penetration. TfR1 CapX™ has been specifically developed to achieve broad distribution throughout the brain and spinal cord, offering the potential for more effective delivery of genetic medicines targeting neurological diseases. Several therapeutic programs utilizing this technology are expected to advance into clinical trials within the next 12 months, demonstrating the platform’s growing translational potential. Through this agreement, FAST gains access to an advanced delivery system that could significantly enhance future Angelman syndrome gene therapy research and clinical development.
Collaboration Strengthens Rare Disease Gene Therapy Research
Angelman syndrome is a rare, lifelong neurogenetic disorder affecting approximately one in 15,000 individuals worldwide. The disease results from loss of function of the UBE3A gene, leading to severe developmental delays, motor impairment, epilepsy, sleep disturbances, and significant communication challenges. Despite ongoing advances in neuroscience, effective disease-modifying therapies remain limited. FAST has become one of the world’s leading non-governmental supporters of Angelman syndrome research, continuously investing in innovative therapeutic technologies that may improve patient outcomes. Company representatives emphasized that addressing complex neurological diseases requires integrating multiple scientific approaches, including advanced vector engineering, targeted gene delivery, and collaborative research partnerships. Access to TfR1 CapX™ provides FAST with a promising technology capable of supporting future investigational gene therapy programs aimed at restoring neuronal function while expanding scientific understanding of CNS-targeted genetic medicine.
Advertisement
Strategic Partnership Advances Precision Gene Therapy Innovation
The agreement highlights the increasing collaboration between patient advocacy organizations and biotechnology companies in accelerating innovation for rare genetic diseases. Apertura Gene Therapy, founded on technology originating from the Broad Institute, specializes in developing next-generation AAV capsids capable of delivering genetic medicines to challenging tissues with improved precision and efficiency. Supported by Deerfield Management, the company has already licensed its proprietary capsid technologies to multiple research and commercial partners pursuing therapies for neurological and genetic disorders. The collaboration with FAST reinforces Apertura’s growing role in advancing precision gene delivery platforms while expanding opportunities for future clinical development. As demand for improved CNS-targeted gene therapies continues to grow, the partnership represents another important milestone in advancing innovative treatment strategies that may ultimately improve the lives of individuals affected by Angelman syndrome and other rare neurological diseases.
Source: Apertura Gene Therapy press release
